๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 15 Beijing 11 Guangzhou 11 Chengdu 8 Chongqing 7
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai15 Beijing11 Guangzhou11 Chengdu8 Chongqing7
All 32 locations
Target enrolment
to

Trials with a site in Shanghai

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
NCT07697586NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
206
Jilin City, Shanghai
2026-08-07
Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
NCT07668154HNSCC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Chengdu, Shanghai
2026-07-27
Recruiting
SKB118 Injection in Advanced Solid Tumors
NCT07586943Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
530
Shanghai
2026-06-01
Recruiting
SKB103 for Injection in Advanced Solid Tumors
NCT07459998Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
277
Harbin, Shanghai
2026-04-23
Recruiting
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
NCT07448922Advanced Gynecological Malignancies
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
280
Chongqing, Shanghai
2026-04-08
Recruiting
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
NCT07308106Non-small Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
70
Shanghai
2026-04-03
Recruiting
A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants
NCT07488065Atopic Dermatitis
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
90
Shanghai
2026-03-31
Recruiting
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
NCT07324629Thymic Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
30
Shanghai
2026-03-13
Recruiting
SKB105 for Injection in Advanced Solid Tumors
NCT07380386Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
256
Beijing, Shanghai
2026-03-05
Recruiting
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
NCT07087197Metastatic Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
90
Shanghai
2025-08-15
Recruiting
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
NCT06726369Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
90
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Shanghai, Wuhan
2024-12-12
Recruiting
A Study of SKB518 in Patients With Advanced Solid Tumors
NCT06428331Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2024-07-04
Recruiting
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
NCT06279364Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
524
Shanghai
2024-02-28
Active, closed
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
NCT06968585HER2-positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
365
Shanghai
2023-07-18
Active, closed
A Study of A166 in Patients With Advanced Solid Malignant Tumors
NCT05311397Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
120
Shanghai
2018-08-09
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

13 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 15 studies
PhaseStudiesRecruitingShare
Phase 15433.3%
Phase 25533.3%
Phase 1/23320%
Phase 32113.3%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1513
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.